NURS 6521 Week 9 Quiz .Q&A

Document Content and Description Below

NURS 6521 Week 9 Quiz .Q&A • Question 1 1 out of 1 points A male patient is receiving rituximab therapy for non-Hodgkin's lymphoma. Which of the following would be a priority nursing interven... tion to reduce the risk for cytotoxicity and tumor lysis syndrome? Response Feedback: Ensuring that the patient maintains a normal fluid and electrolyte balance is critical to maintaining a consistent drug dilution in the body and therefore limiting the risk of cytotoxicity and tumor lysis syndrome. Ensuring that the patient maintains a normal breathing pattern, is protected from exposure to infections, and does not develop renal impairment are also important nursing responsibilities; however, they do not help to significantly reduce the risk for cytotoxicity and tumor lysis syndrome. • Question 2 1 out of 1 points An older adult woman has been diagnosed with acute lymphoblastic leukemia (ALL) and her care team has identified potential benefits of imatinib. Which of the following characteristics of this patient's current health status may preclude the use of imatinib? Response Feedback: Imatinib may be associated with edema. Patients should be weighed regularly and assessed for signs of fluid retention that could be severe. The risk of edema increases with higher doses of imatinib and age greater than 65 years. Previous strokes, orthopedic surgery, or well-controlled diabetes may not contraindicate the use of imatinib. • Question 3 1 out of 1 points A 60-year-old patient experienced a sudden onset of chest pain and shortness of breath and was subsequently diagnosed with a pulmonary embolism in the emergency department. The patient has been started on an intravenous heparin infusion. How does this drug achieve therapeutic effect? Response Feedback: Heparin, along with antithrombin, rapidly promotes the inactivation of factor X, which, in turn, prevents the conversion of prothrombin to thrombin. Heparin does not achieve its therapeutic effect through the excretion or inhibition of vitamin K or by inhibiting platelet aggregation. • Question 4 1 out of 1 points A nurse is caring for a patient with cancer who has been prescribed dronabinol (Marinol) to help reduce nausea and vomiting from chemotherapy. The nurse will inform the patient that he or she is taking an oral form of Response Feedback: The major ingredient of Marinol is 9-tetrahydrocannabinol (THC), the active ingredient in marijuana. • Question 5 1 out of 1 points A patient will soon begin targeted therapy as a component of her treatment plan for chronic leukemia. The nurse is conducting health education about this new aspect of the patient's drug regimen and the patient has asked about the potential side effects of treatment. How should the nurse best respond? Response Feedback: Targeted therapies are generally considered to be less toxic than traditional chemotherapy drugs. However, adverse reactions to targeted therapies can occur such as severe skin reactions, GI toxicities, skin reactions, and thrombosis. • Question 6 0 out of 1 points When planning care for a patient who is receiving filgrastim (Neupogen) for a nonmyeloid malignancy, the nurse should formulate which of the following patient outcomes? (Select all that apply.) Response Feedback: Desired outcomes for a patient receiving filgrastim include that febrile neutropenia will be avoided and infection and bone pain will not develop, or at least bone pain will not be unmanageable if it develops. Also, because this drug is administered subcutaneously every day during therapy, management of their own administration would be a positive outcome for patients. A patient who is taking oprelvekin would be at risk for fluid retention. Filgrastim is not associated with this adverse effect. • Question 7 1 out of 1 points A nurse is assessing a patient who has chronic lymphoblastic myelogenous leukemia. The treatment plan includes hydroxyurea (Hydrea). The nurse will assess the patient for which of the following? Response Feedback: Hydroxyurea may be contraindicated in patients with low WBCs. The drug is not contraindicated with diabetes mellitus, hypertension, or hypoglycemia. • Question 8 0 out of 1 points A patient with a recent diagnosis of chronic myelogenous leukemia (CML) is discussing treatment options with his care team. What aspect of the patient's condition would contraindicate the use of cyclophosphamide for the treatment of leukemia? Response Feedback: Patients with severely compromised bone marrow functions cannot tolerate treatment with cyclophosphamide. Diabetes, impaired renal function, and previous nonadherence to treatment must be addressed when planning the patient's care, but these factors do not necessarily contraindicate the use of cyclophosphamide. • Question 9 1 out of 1 points A 45-year-old woman with acute leukemia is going to begin chemotherapy with vincristine. The nurse is aware that vincristine must always be administered Response Feedback: If vincristine is administered as a continuous infusion, a central line should always be used. It is important to prime IV lines for chemotherapy administration with 5% dextrose in water or normal saline, not with vincristine, before administering the drug. The infusion rate, although important, is not as important a factor for vincristine administration as is the need for a central line. • Question 10 1 out of 1 points A 67-year-old man who is being treated for prostate cancer is taking epoetin alfa. The nurse will instruct the patient to Response Feedback: After each dose adjustment, the nurse should ensure that the patient makes an appointment to have the hemoglobin measured twice a week for at least 2 to 6 weeks to verify that it is in the normal range. A high WBC count and hypertension have not been identified as adverse effects of epoetin alfa. ...........CONTINUED [Show More]

Last updated: 2 years ago

Preview 1 out of 10 pages